Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542758 | 0.87 | FFAR2 (0.35) | FFAR2LMNA | |
| SCHEMBL21542864 | 0.85 | HTT (0.40) | FFAR2LMNA | |
| SCHEMBL21542732 | 0.73 | HSP90AA1 (0.32) | FFAR2LMNA | |
| SCHEMBL29824433 | 0.73 | HSP90AA1 (0.32) | FFAR2LMNA | |
| SCHEMBL23234668 | 0.72 | HRH4 (0.33) | LMNA | |
| SCHEMBL21608277 | 0.72 | NOS2 (0.52) | LMNA | |
| SCHEMBL29614779 | 0.70 | NOS3 (0.32) | — | |
| SCHEMBL29008177 | 0.70 | NOS3 (0.32) | — | |
| SCHEMBL22720430 | 0.70 | NOS3 (0.32) | — | |
| SCHEMBL21543532 | 0.70 | LMNA (0.41) | FFAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357272-A1 | OCTAHYDROPYRAZINODIAZANAPHTHYRIDINE DIONE COMPOUNDS | MEDSHINE DISCOVERY INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357272-A1 | OCTAHYDROPYRAZINODIAZANAPHTHYRIDINE DIONE COMPOUNDS | MEDSHINE DISCOVERY INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-4129997-A1 | OCTAHYDROPYRAZINODIAZANAPHTHYRIDINE DIONE COMPOUNDS | Medshine Discovery Inc. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-112159405-B | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| CN-112159405-A | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357272-A1 | OCTAHYDROPYRAZINODIAZANAPHTHYRIDINE DIONE COMPOUNDS | QDPR, SLCO1B3, SLC10A6 | FFAR2 1098/4885LMNA 4537/4885 |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | FFAR2 2094/4885LMNA 3223/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | FFAR2 2094/4885LMNA 3223/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | FFAR2 544/4885LMNA 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.